Announced
Completed
Synopsis
Eli Lilly, an American pharmaceutical company and Santec Holdings, a global photonics company and a manufacturer, led a JPY1.5bn Series C funding round in PRISM BioLab, a discovery and development biotechnology company. We feel confident that PRISM BioLab's promising and unique approach to drug discovery will lead to breakthrough therapeutic drugs that were previously unattainable. Santec is engaged in the development of medical imaging devices and early diagnosis utilizing Photonics. We believe that the advancement of these technologies, in conjunction with innovative drug discovery techniques, is pivotal for the comprehensive improvement of patients' Quality of Life. Changho Chong, Santec Holdings Executive Vice President & CTO.
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.